Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2021-07-13 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
第四届董事会第二十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from a company's board of directors, detailing the approval of a proposal related to the use of raised funds. It includes meeting attendance, voting results, and references to related disclosures on a regulatory website. There is no detailed financial data or full report content, but rather a formal announcement of a board decision. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management.
2021-07-13 Chinese
独立董事关于公司第四届董事会第二十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on a specific board meeting matter related to the use of raised funds and compliance with regulatory guidelines. It references regulatory bodies and company governance documents but does not contain financial statements or detailed financial data. The document is short (487 characters) and serves as an official opinion rather than a full report or announcement of voting results. It fits best under Board/Management Information (MANG) as it relates to board decisions and governance matters.
2021-07-13 Chinese
第四届监事会第二十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of a company regarding the approval of a proposal to use raised funds to replace previously invested self-raised funds. It includes details about the meeting, voting results, and references to regulatory compliance and related reports. The document is short (857 characters) and serves as an official announcement of a board decision rather than a full financial report or detailed audit. It does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2021-07-13 Chinese
国浩律师（深圳）事务所关于公司创业板向不特定对象发行可转换公司债券并在深圳证券交易所上市之法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the issuance and listing of convertible corporate bonds by a company on the Shenzhen Stock Exchange. It extensively references Chinese securities laws, company laws, regulatory approvals from the China Securities Regulatory Commission (CSRC), Shenzhen Stock Exchange, and detailed compliance with issuance conditions. The document is a standalone legal opinion related to a capital market transaction (issuance of convertible bonds) and does not contain financial statements or earnings data. It is not an annual or interim report, earnings release, or investor presentation. It is not a proxy, voting result, or management change announcement. The document is a legal opinion report related to audit and regulatory compliance for a financing transaction. Therefore, it fits best under the category Audit Report / Information (AR), which includes standalone audit reports, applied accounting principles, and regulatory compliance documents excluding full annual reports. The document length (over 10,000 characters) and detailed legal content confirm it is the report itself, not just an announcement. Hence, the classification is AR with high confidence. Q1 2021
2021-07-07 Chinese
中航证券有限公司关于公司创业板向不特定对象发行可转换公司债券之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is a detailed listing sponsorship letter (上市保荐书) from 中航证券有限公司 regarding the issuance of convertible bonds by 健帆生物科技集团股份有限公司. It includes extensive information about the issuer, business overview, core technologies, financial data, risk factors, and detailed terms of the convertible bond issuance such as issuance scale, interest rates, conversion price adjustments, and redemption clauses. The document is not a financial report like an annual or interim report, nor is it a brief announcement or a certification. It is a comprehensive capital/financing update related to a bond issuance and listing sponsorship. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-07-07 Chinese
创业板向不特定对象发行可转换公司债券上市公告书
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the issuance and listing of convertible corporate bonds by Jafron Biomedical Co., Ltd. It includes extensive information about the bond issuance, terms, underwriting, credit rating, issuance scale, pricing, conversion terms, redemption clauses, and shareholder information. The document is titled as a "上市公告书" (Listing Announcement) for convertible bonds and contains no financial statements or earnings data. It is not an annual or interim report, nor an earnings release or management discussion. It is a formal announcement of a capital market transaction related to financing activities, specifically the issuance and listing of convertible bonds. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed terms and conditions of the bond issuance, supporting a high confidence in classification.
2021-07-07 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.